Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 1A-B (Cert # L239181)

Teaser: This course is a collection of journal articles that focus on advances across the oncology specialty practice domains. It is a series of current articles from the primary oncology literature.

Tag: Certifications; Oncology

ACPE Numbers: Various – see listing below
Pre-Sale Date: 02/22/2023
Content Release Date: 03/22/2023
Expiration Dates: 09/26/2023
Activity Type: Application-based
CE Credits: 8 contact hours
Activity Fee: $160 (ASHP member); $215 (non-member)

Accreditation for Pharmacists
The American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience
These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

- Pharmacogenomics
- Statistics
- Pediatric Malignancy
- Hepatocellular Carcinoma
- Urothelial Carcinoma
- Pharmacy Practice Management
- Lymphoma

Activity Overview
The Home Study Syllabus is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice.

Learners will be required to review the content of the articles and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.

Recertification Credit*

Board certified pharmacists are eligible to receive up to 8 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

<table>
<thead>
<tr>
<th>Learning Activity</th>
<th>ACPE Number</th>
<th>Contact Hours</th>
<th>Assessment Pass Point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Home Study Syllabus Module 1A: Pharmacogenomics, Statistics, Pediatric Malignancy</td>
<td>0204-9999-23-952-H01-P</td>
<td>4 ACPE</td>
<td>TBD</td>
</tr>
<tr>
<td>Home Study Syllabus Module 1B: Hepatocellular Carcinoma, Urothelial Carcinoma, Pharmacy Practice Management, Lymphoma</td>
<td>0204-9999-23-953-H01-P</td>
<td>4 ACPE</td>
<td>TBD</td>
</tr>
<tr>
<td>Recertification Assessment</td>
<td></td>
<td>8 BPS</td>
<td></td>
</tr>
</tbody>
</table>

Articles and Learning Objectives

Module 1A: Pharmacogenomics, Statistics, Pediatric Malignancy
ACPE #: 0204-9999-23-952-H01-P


Learning Objectives:
- Describe the provisional clinical opinion from the American Society of Clinical Oncology (ASCO) for the use of somatic genomic testing and biomarker-guided therapies in patients with metastatic or advanced cancer.
- Develop recommendations for the use of somatic genomic testing and biomarker-guided therapies in patients with metastatic or advanced cancer.
- Select appropriate patients to receive biomarker-guided therapies based on the ASCO provisional clinical opinion for somatic genomic testing.


Learning Objectives:
- Describe various endpoints used in an immuno-oncology trial.
- Select appropriate patients to receive nivolumab in combination for a patient with advanced esophageal squamous-cell carcinoma based on the results of an immuno-oncology trial.
- Interpret an immuno-oncology trial using nivolumab in combination for a patient with advanced esophageal squamous-cell carcinoma.
Brown PA, Ji L, Xu X et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021; 325(9):833–842.

Learning Objectives:
• Describe the study of blinatumomab for relapsed B-cell acute lymphoblastic leukemia in children, adolescents and young adults with first relapse.
• Select appropriate patients to receive blinatumomab based on the results of the study by Brown, et al.
• Develop recommendations for the management of first relapse of B-cell acute lymphoblastic leukemia in children, adolescents and young adults.

Module 1B: Hepatocellular Carcinoma, Urothelial Carcinoma, Pharmacy Practice Management, Lymphoma
ACPE #: 0204-9999-23-953-H01-P


Learning Objectives:
• Describe the COSMIC-312 study of cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma.
• Develop recommendations for the use of cabozantinib plus atezolizumab in patients with advanced hepatocellular carcinoma.
• Select appropriate patients to receive cabozantinib plus atezolizumab based on the results of the COSMIC-312 study.


Learning Objectives:
• Describe the study of adjuvant nivolumab for muscle-invasive bladder cancer in newly diagnosed patients following surgical resection.
• Develop recommendations for the use of adjuvant nivolumab in patients with muscle-invasive bladder cancer.
• Select appropriate patients to receive adjuvant nivolumab based on the results of CheckMate 274 by Bajorin et al.


Learning Objectives:
• Describe the overview of biosimilar agents for the therapeutic use in cancer from the American Society of Clinical Oncology (ASCO).
• Develop recommendations for the use of biosimilars for therapeutic use in oncology patients and inclusion in future ASCO clinical guidelines.
• Select appropriate patients to receive biosimilar medications based on the ASCO summary of the current agents available for the therapeutic treatment of cancer.

Learning Objectives:
- Describe the TRANSFORM study of lisocabtagene maraleucel versus the standard of care for the second-line treatment of relapsed or refractory large B-cell lymphoma.
- Develop recommendations for the use of lisocabtagene maraleucel for the second-line treatment of diffuse large B-cell lymphoma.

Faculty  
([https://www.rxcertifications.org/Oncology/Course-Faculty](https://www.rxcertifications.org/Oncology/Course-Faculty))

**John Bossaer, PharmD, BCOP**  
Professor  
Bill Gatton East Tennessee State University College of Pharmacy  
Johnson City, Tennessee

**Courtney C. Cavalieri, PharmD, BCOP***  
Clinical Oncology Pharmacist  
Huntsman Cancer Institute at the University of Utah  
Salt Lake City, Utah

**Karen M. Fancher, PharmD, BCOP***  
Associate Professor of Pharmacy Practice/ Clinical Pharmacy Specialist - Oncology  
Duquesne University School of Pharmacy/UPMC  
Passavant Hospital  
Pittsburgh, Pennsylvania

**Christopher Fausel, PharmD, MHA, BCOP**  
Director of Pharmacy - Precision Genomics  
Indiana University Health  
Indianapolis, Indiana

**Elyse A. MacDonald, PharmD, MS, BCPS**  
Director, Pharmacy Services, Investigational Drug Service  
Stanford Health Care  
Palo Alto, California

**Christine M. Walko, PharmD, BCOP, FCCP***  
Senior Member, Individualized Cancer Management; Precision Medicine Program Lead  
H. Lee Moffitt Cancer Center  
Tampa, Florida

**Jennifer Young, PharmD, BCOP**  
Clinical Pharmacy Specialist - Pediatric Hematology / Oncology  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, Ohio

*Content Matter Experts*
Disclosures
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

- Karen Fancher: Consultant, AstraZeneca, Merck
- Courtney Cavilieri: Consultant, Pfizer
- All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Methods and CE Requirements
Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements
Learning activities are delivered via your Web browser and Acrobat PDF. For all activities you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.

Development
ASHP collaborates with ACCP on oncology activities.